Researchers at Nagoya University have pinpointed a partnership between two gut microorganisms—Akkermansia muciniphila and Bacteroides thetaiotaomicron—that appears to erode the protective mucus coating of the colon. This coating, rich in mucin, keeps stool hydrated and sliding smoothly through the intestines. When it is stripped away, waste hardens, leading to persistent constipation.
The study, published in *Gut Microbes*, sheds light on why conventional laxatives often fall short for millions suffering from long‑term constipation. Moreover, the researchers observed a striking overlap with Parkinson’s disease: patients with the neurodegenerative disorder showed elevated levels of the same mucus‑degrading bacteria, suggesting a microbial contribution to the early constipation that precedes motor symptoms.
Why the Mucus Layer Matters
Constipation is commonly blamed on sluggish gut motility, yet many individuals experience the condition without any clear slowdown. This idiopathic form, as well as the severe constipation seen in Parkinson’s patients, can be traced back to a breakdown of the mucin gel that lines the large intestine. Mucin not only lubricates stool but also shields the epithelium from bacterial invasion.
In the newly described mechanism, B. thetaiotaomicron initiates the assault by secreting sulfatase enzymes that strip away sulfate groups protecting mucin. Once those defenses are removed, A. muciniphila moves in and digests the now‑exposed protein backbone. The resulting depletion of mucus leaves the colon dry, turning normally soft waste into hard, difficult‑to‑pass pellets.
Beyond Laxatives: Targeting Bacterial Enzymes
To test whether halting this enzymatic cascade could avert constipation, the team engineered a version of B. thetaiotaomicron lacking active sulfatase. When introduced into germ‑free mice alongside A. muciniphila, the animals maintained a intact mucus layer and displayed normal stool consistency, unlike their unmodified counterparts.
These findings point to sulfatase inhibition as a promising therapeutic avenue. By protecting mucin from bacterial degradation, future drugs could address the root cause of “bacterial constipation” rather than merely stimulating intestinal movement.
Implications for Parkinson’s and General Gut Health
The link between mucus‑degrading microbes and Parkinson’s‑related constipation suggests that microbiome‑focused interventions might delay or mitigate early non‑motor symptoms of the disease. For the broader population, strategies that preserve or restore the colonic mucus barrier could complement existing treatments, offering relief to those who have struggled with chronic constipation for decades.